{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:32:24Z","timestamp":1787499144080,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cld.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:27:29Z","timestamp":1648798049000},"page":"213-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Emily","family":"Truong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2022.01.008_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.008_bib3","unstructured":"The top 10 causes of death. World Health Organization."},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib5","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.cld.2022.01.008_bib7","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice Guidance from the American association for the study of liver diseases","author":"Chalasani","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and Noninvasive Measurement of steatosis in patients with biopsy-Proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"32","key":"10.1016\/j.cld.2022.01.008_bib9","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2022.01.008_bib12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A\u00a0blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2022.01.008_bib13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s10620-016-4079-4","article-title":"Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016","volume":"61","author":"Kaswala","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.aohep.2019.07.013","article-title":"Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the Hepatologist should know?","volume":"19","author":"Kiapidou","year":"2020","journal-title":"Ann Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2022.01.008_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cld.2022.01.008_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metab Clin Exp"},{"issue":"6","key":"10.1016\/j.cld.2022.01.008_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2022.01.008_bib19","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2215\/CJN.05050610","article-title":"Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis","volume":"5","author":"Targher","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.09.020","article-title":"Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes","volume":"68","author":"Yeung","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/0886022X.2015.1106845","article-title":"Increased microalbuminuria prevalence among patients with nonalcoholic fatty liver disease","volume":"38","author":"Kasapoglu","year":"2016","journal-title":"Ren Fail"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/lt.25694","article-title":"Chronic kidney disease in liver transplant Candidates: a rising burden impacting post\u2013liver transplant outcomes","volume":"26","author":"Cullaro","year":"2020","journal-title":"Liver Transplant"},{"issue":"9","key":"10.1016\/j.cld.2022.01.008_bib23","doi-asserted-by":"crossref","first-page":"e040970","DOI":"10.1136\/bmjopen-2020-040970","article-title":"Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease","volume":"10","author":"Hydes","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.cld.2022.01.008_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.cld.2022.01.008_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","article-title":"Emerging liver-kidney interactions in nonalcoholic fatty liver disease","volume":"21","author":"Musso","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cld.2022.01.008_bib26","article-title":"Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease","author":"Kanbay","year":"2020","journal-title":"J\u00a0Nephrol"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jnutbio.2013.11.010","article-title":"Betaine supplementation protects against high-fructose-induced renal injury in rats","volume":"25","author":"Fan","year":"2014","journal-title":"J\u00a0Nutr Biochem"},{"issue":"12","key":"10.1016\/j.cld.2022.01.008_bib28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/hep4.1271","article-title":"Mitochondrial oxidative stress and antioxidants balance in fatty liver disease","volume":"2","author":"Garc\u00eda-Ruiz","year":"2018","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-12-165","article-title":"Nrf2 deletion causes \u201cbenign\u201d simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet","volume":"12","author":"Wang","year":"2013","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.01.008_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2022.01.008_bib32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbadis.2016.10.002","article-title":"Fetuin-A downregulates adiponectin through Wnt-PPAR\u03b3 pathway in lipid induced inflamed adipocyte","volume":"1863","author":"Agarwal","year":"2017","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000452880","article-title":"Klotho\/FGF23 Axis in chronic kidney disease and cardiovascular disease","volume":"3","author":"Lu","year":"2017","journal-title":"Kidney Dis"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep.26319","article-title":"Intestinal microbiota in patients with nonalcoholic fatty liver disease","volume":"58","author":"Mouzaki","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2022.01.008_bib36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cgh.2013.02.015","article-title":"Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease","volume":"11","author":"Raman","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.01.008_bib37","first-page":"65","article-title":"Chapter three - the role of the gut microbiome on chronic kidney disease","volume":"96","author":"Sampaio-Maia","year":"2016"},{"key":"10.1016\/j.cld.2022.01.008_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trsl.2016.04.007","article-title":"Gut microbiome in chronic kidney disease: challenges and opportunities","volume":"179","author":"Nallu","year":"2017","journal-title":"Translational Res"},{"issue":"7341","key":"10.1016\/j.cld.2022.01.008_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cld.2022.01.008_bib40","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty liver and chronic kidney disease: novel mechanistic insights and therapeutic opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.5114\/aoms.2016.58831","article-title":"The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention","volume":"14","author":"Vespasiani-Gentilucci","year":"2018","journal-title":"Arch Med Sci"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ijo.2014.153","article-title":"The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents","volume":"39","author":"Psichas","year":"2015","journal-title":"Int J Obes"},{"issue":"5","key":"10.1016\/j.cld.2022.01.008_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ijms20051214","article-title":"Secondary bile acids and short chain fatty acids in the colon: a Focus on colonic microbiome, cell proliferation, inflammation, and cancer","volume":"20","author":"Zeng","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib44","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/1354750X.2012.749302","article-title":"Clinical and research markers of oxidative stress in chronic kidney disease","volume":"18","author":"Tucker","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.cld.2022.01.008_bib45","series-title":"The non-thrombotic role of platelets in health and disease","article-title":"Role of platelets in inflammation","author":"Arman","year":"2015"},{"issue":"19","key":"10.1016\/j.cld.2022.01.008_bib46","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","article-title":"Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease\u2013associated thrombosis in mice","volume":"129","author":"Yang","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.cld.2022.01.008_bib47","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.3748\/wjg.v20.i23.7260","article-title":"Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update","volume":"20","author":"Elpek","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.cld.2022.01.008_bib49","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cld.2022.01.008_bib50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","article-title":"Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2022.01.008_bib51","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.12656","article-title":"PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease","volume":"30","author":"Shen","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2022.01.008_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039362","article-title":"Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant","volume":"7","author":"Palmer","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib55","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1111\/hepr.12552","article-title":"Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus","volume":"46","author":"Kan","year":"2016","journal-title":"Hepatol Res"},{"issue":"10","key":"10.1016\/j.cld.2022.01.008_bib56","article-title":"The I148M variant of PNPLA3 reduces the response to Docosahexaenoic acid in children with non-alcoholic fatty liver disease","volume":"16","author":"Nobili","year":"2013","journal-title":"J\u00a0Med Food"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2014.02.002","article-title":"Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease","volume":"37","author":"Scorletti","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.cld.2022.01.008_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2022.01.008_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.37349\/emed.2020.00004","article-title":"PNPLA3 gene and kidney disease","volume":"1","author":"Mantovani","year":"2020","journal-title":"Exploration Med"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.01.008_bib61","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1152\/ajpgi.00212.2007","article-title":"Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1","volume":"293","author":"Radaeva","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cld.2022.01.008_bib62","author":"de Vries"},{"issue":"4","key":"10.1016\/j.cld.2022.01.008_bib63","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney Hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.cld.2022.01.008_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.cld.2022.01.008_bib65","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of Subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib66","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"10019","key":"10.1016\/j.cld.2022.01.008_bib68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.cld.2022.01.008_bib69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4239\/wjd.v10.i2.114","article-title":"SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review","volume":"10","author":"Raj","year":"2019","journal-title":"World J Diabetes"},{"issue":"5","key":"10.1016\/j.cld.2022.01.008_bib70","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease","volume":"38","author":"Mima","year":"2021","journal-title":"Adv Ther"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:12Z","timestamp":1761069552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1089326122000083"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}